Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.110 -0.050 (-4.31%)

Official Closing Price Updated: 6:30 PM EDT, Aug 28, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	587,284
Open	1.160
Bid (Size)	1.110 (500)
Ask (Size)	1.140 (2,500)
Prev. Close	1.160
Today's Range	1.110 - 1.176
52wk Range	1.000 - 2.090
Shares Outstanding	174,986,671
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

CEO outlines manufacturing scale-up strategy for cell therapies amid $50.8M cash runway.

Via The Motley Fool

Lineage Cell Therapeutics Q2 Earnings Call Highlights ↗

August 09, 2026

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type...

Via MarketBeat

Performance

YTD	-32.3%	-32.3%
1 Month	+3.7%	+3.7%
3 Month	-16.5%	-16.5%
6 Month	-43.4%	-43.4%
1 Year	-9.0%	-9.0%

More News

Lineage Cell Therapeutics (NYSEARCA:LCTX) Slips on Q2 Revenue Miss, but EPS In Line and Pipeline Advances ↗

August 06, 2026

Via Chartmill

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 06, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics (NYSEARCA:LCTX) Q1 2026 Results: Revenue Miss and Increased Losses Weigh on Investor Sentiment ↗

May 12, 2026

Via Chartmill

Lineage Cell Therapeutics (LCTX) Reports Q4 Revenue Beat and Narrowed Loss ↗

March 05, 2026

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

July 30, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject’ Cell Therapy Plan ↗

July 14, 2026

Via MarketBeat

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

July 13, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

July 06, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call ↗

July 01, 2026

Via Benzinga

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

May 20, 2026

Via FinancialNewsMedia

Lineage Cell Therapeutics Q1 Earnings Call Highlights ↗

May 15, 2026

Via MarketBeat

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

May 05, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

May 04, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Announces Formation of Scientific Advisory Board

April 13, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

March 24, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 05, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

February 26, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

January 06, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Issues Letter to Stockholders

January 05, 2026

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Inc (NYSEARCA:LCTX) Reports Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗

November 06, 2025

Via Chartmill

Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

November 06, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Lineage Cell Therapeutics, Inc. Common Stock publicly traded?

Yes, Lineage Cell Therapeutics, Inc. Common Stock is publicly traded.

What exchange does Lineage Cell Therapeutics, Inc. Common Stock trade on?

Lineage Cell Therapeutics, Inc. Common Stock trades on the New York Stock Exchange

What is the ticker symbol for Lineage Cell Therapeutics, Inc. Common Stock?

The ticker symbol for Lineage Cell Therapeutics, Inc. Common Stock is LCTX on the New York Stock Exchange

What is the current price of Lineage Cell Therapeutics, Inc. Common Stock?

The current price of Lineage Cell Therapeutics, Inc. Common Stock is 1.110

When was Lineage Cell Therapeutics, Inc. Common Stock last traded?

The last trade of Lineage Cell Therapeutics, Inc. Common Stock was at 08/28/26 06:30 PM ET

What is the market capitalization of Lineage Cell Therapeutics, Inc. Common Stock?

The market capitalization of Lineage Cell Therapeutics, Inc. Common Stock is 194.24M

How many shares of Lineage Cell Therapeutics, Inc. Common Stock are outstanding?

Lineage Cell Therapeutics, Inc. Common Stock has 194M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.